Recommendation for treatment for patients suffering from Benign Prostate Enlargement

The medications currently available on the formulary are, the alpha-blockers Doxazosin 2mg and uroselective Alfuzosin 10mg prolonged release; and the 5-alpha-reductase inhibitors (5-ARI) Finasteride 5mg and Dutasteride 0.5mg. Patients who are established and doing well on doxazosin and finasteride should remain on the same treatment. New cases or patients intolerant of the medication may be switched to the uroselective alternative.

Name ID Age DOB
Date Telephone Address
Affix Label here
Medical Practitioner Name Medical Reg No.
Signature
Please tick current alpha blocker treatment if any *
FAMIA
Alfuzosin 10mg XL □ Tamsulosin 0.4mg □ Doxazosin 4mg XL □ Silodosin 8mg □
Doxazosin 2mg ☐ Doxazosin 4mg ☐ Terazosin 2mg ☐ Terazosin 5mg ☐
Others, please state name and dosage
Patient Safety notice
Caution is advised when switching from one of the uroselective or prolonged release medications to the short acting doxazosin, especially when the dose equivalent of 4mg doxazosin is being contemplated and especially in patients that are prone to getting hypotensive episodes such as the frail and elderly.
For patients starting 5-ARI's it is recommended that a baseline PSA is taken.
I hereby declare that I have read this safety information and taken it into account. \square *
* Required fields. Forms without these fields will be returned to the sender unsigned.
PART B Prescribed Schedule V medication
Tick the required treatment/s from the list below. When treatment with the alpha blocker is not sufficient, a 5-ARI may be added.
Doxazosin 2mg Finasteride 5mg Alfuzosin 10mg XL Dutasteride 0.5mg
PART C
Is the patient already under consultant urology supervision? Yes No Name
Approved Yes No Consultant Signature/ Reg No
Rubber Stamp